Highlights Invivyd, Inc.

Equities

IVVD

US00534A1025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
1.17 ^USD	+4.46%		+6.36%	-70.30%

Jul. 01	Invivyd Joining Russell 2000, 3000 Indexes	MT
Jul. 01	Invivyd, Inc.(NasdaqGM:IVVD) added to Russell Small Cap Comp Value Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Invivyd Joining Russell 2000, 3000 Indexes	Jul. 01	MT
Invivyd Announces Antiviral Activity of VYD222 Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants	Jun. 14	CI
Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies	May. 31	CI
Invivyd, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback	May. 07	CI
Invivyd's Pemgarda Injection to Prevent Covid Available in US -- Shares Rise After Hours	Apr. 04	MT
Invivyd Sees Covid-19 Prevention Treatment Revenue of Up to $200 Million This Year	Apr. 04	DJ
Invivyd, Inc. Provides Earnings Guidance for the Year 2024	Apr. 04	CI
Invivyd, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Top Premarket Gainers	Mar. 26	MT
Invivyd Receives Upgrade to Overweight From Equalweight From Morgan Stanley, Price Target Raised to $10 From $4 Amid Pemgarda FDA Authorization	Mar. 26	MT
Invivyd Shares Give Back Some Gains After Surge From FDA Emergency Approval	Mar. 22	DJ
Invivyd's Covid Treatment for Immunodeficiency Disorders Gets FDA Nod; Shares Up Before Trading Halt	Mar. 22	MT
Invivyd, Inc. Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial	Mar. 22	CI
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA? (Formerly VYD222) for Pre-exposure Prophylaxis of COVID-19	Mar. 22	CI
Invivyd Files Emergency Use Authorization Application for Antibody Candidate Against COVID-19	Jan. 03	MT
Invivyd Submits Request for Emergency Use Authorization to U.S. FDA for VYD222 for the Pre-Exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents	Jan. 03	CI
North American Morning Briefing : S&P 500 Futures -2-	Dec. 20	DJ
Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19	Dec. 18	CI
Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Invivyd, Inc.

Equities

IVVD

US00534A1025

Highlights

Filters